Novartis lights up radiopharmaceuticals again
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
The $1bn price tag for the preclinical Mariana Oncology shows that competition for assets in this space is fierce.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Genmab’s remarkably bold acquisition raises more questions about Sutro, a key FRα rival of ProfoundBio.
A $44m up-front for the tumour-activated IL-12 XTX301 will help keep Xilio going until 2025.